# Safety and Effectiveness of Apixaban in Very Elderly Patients With Non-valvular Atrial Fibrillation (NVAF) Compared to Warfarin Using Administrative Claims Data

> **NCT05438888** · — · COMPLETED · sponsor: **Pfizer** · enrollment: 77814 (actual)

## Conditions studied

- Non-valvular Atrial Fibrillation

## Interventions

- **DRUG:** Warfarin
- **DRUG:** Apixaban

## Key facts

- **NCT ID:** NCT05438888
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2022-07-01
- **Primary completion:** 2022-10-19
- **Final completion:** 2022-10-19
- **Target enrollment:** 77814 (ACTUAL)
- **Last updated:** 2024-05-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05438888

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05438888, "Safety and Effectiveness of Apixaban in Very Elderly Patients With Non-valvular Atrial Fibrillation (NVAF) Compared to Warfarin Using Administrative Claims Data". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT05438888. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*